Nxera Pharma Grows Revenue but Widens Loss on R&D and Finance Costs in 2025

An update from Sosei Group ( (JP:4565) ) is now available.

Nxera Pharma reported a modest 2.7% year‑on‑year increase in revenue to ¥29.6 billion for the year ended December 2025, driven by strong growth in sales of its commercialized products PIVLAZ and QUVIVIQ. PIVLAZ revenue rose 6.8% to ¥13.5 billion and QUVIVIQ surged 223.9% to ¥4.3 billion, partially offsetting a decline in milestone income despite a higher number of milestones achieved.

The company’s operating loss widened to ¥8.5 billion as higher research and development spending, particularly on clinical‑stage programs in obesity and metabolic diseases and the impact of yen depreciation, outweighed cost savings in selling, general and administrative expenses. Additional finance costs tied to amended bond terms and remeasurement of contingent consideration pushed loss before tax to ¥15.0 billion and net loss attributable to shareholders to ¥12.5 billion, underscoring the earnings pressure from Nxera’s investment‑led growth strategy.

The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.

More about Sosei Group

Nxera Pharma is a technology‑driven biopharmaceutical company focused on developing and commercializing specialty medicines for patients with unmet medical needs in Japan and globally. It has an agile commercial business in Japan and the broader Asia‑Pacific region and advances an extensive pipeline using its NxWave GPCR structure‑based drug discovery platform, operating from hubs in Japan, the U.K., Switzerland and South Korea and listed on the Tokyo Stock Exchange.

Average Trading Volume: 875,488

Technical Sentiment Signal: Sell

Current Market Cap: Yen80.36B

See more data about 4565 stock on TipRanks’ Stock Analysis page.